Q1 2023 Earnings Estimate for Leap Therapeutics, Inc. (NASDAQ:LPTX) Issued By HC Wainwright

Leap Therapeutics, Inc. (NASDAQ:LPTX – Get Rating) – Stock analysts at HC Wainwright raised their Q1 2023 earnings per share (EPS) estimates for shares of Leap Therapeutics in a note issued to investors on Wednesday, January 18th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.05) for the quarter, up from their prior forecast of ($0.11). HC Wainwright has a “Buy” rating and a $2.50 price objective on the stock. The consensus estimate for Leap Therapeutics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Leap Therapeutics’ Q2 2023 earnings at ($0.05) EPS, Q3 2023 earnings at ($0.05) EPS, Q4 2023 earnings at ($0.04) EPS, FY2023 earnings at ($0.19) EPS, FY2024 earnings at ($0.23) EPS, FY2025 earnings at ($0.06) EPS and FY2026 earnings at $0.12 EPS.

Other equities research analysts have also issued research reports about the stock. Piper Sandler dropped their price objective on shares of Leap Therapeutics from $4.00 to $3.00 in a research note on Tuesday. Robert W. Baird dropped their price target on Leap Therapeutics to $4.00 in a research report on Monday, November 21st. Finally, Raymond James reduced their price objective on Leap Therapeutics from $3.50 to $2.50 and set an “outperform” rating for the company in a research report on Friday, November 11th.

Leap Therapeutics Stock Performance

Leap Therapeutics stock opened at $0.72 on Friday. Leap Therapeutics has a 1 year low of $0.40 and a 1 year high of $2.57. The firm’s 50-day moving average is $0.53 and its 200-day moving average is $0.90. The company has a market cap of $71.21 million, a P/E ratio of -1.53 and a beta of 0.59.

Leap Therapeutics (NASDAQ:LPTX – Get Rating) last announced its quarterly earnings data on Monday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02).

Institutional Investors Weigh In On Leap Therapeutics

Several large investors have recently made changes to their positions in the company. Virtu Financial LLC boosted its position in shares of Leap Therapeutics by 44.2% during the second quarter. Virtu Financial LLC now owns 28,865 shares of the company’s stock worth $33,000 after buying an additional 8,852 shares during the period. Gilman Hill Asset Management LLC boosted its position in Leap Therapeutics by 80.0% during the 2nd quarter. Gilman Hill Asset Management LLC now owns 22,500 shares of the company’s stock worth $26,000 after acquiring an additional 10,000 shares during the period. Private Advisor Group LLC grew its stake in shares of Leap Therapeutics by 104.5% in the first quarter. Private Advisor Group LLC now owns 22,500 shares of the company’s stock worth $39,000 after purchasing an additional 11,500 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Leap Therapeutics by 1.2% during the first quarter. BlackRock Inc. now owns 1,198,188 shares of the company’s stock valued at $2,098,000 after purchasing an additional 14,079 shares during the period. Finally, Integrated Wealth Concepts LLC bought a new stake in shares of Leap Therapeutics during the first quarter valued at about $26,000. Institutional investors and hedge funds own 37.44% of the company’s stock.

About Leap Therapeutics

(Get Rating)

Leap Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR.